Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Silo Pharma Inc (SILO)

Silo Pharma Inc (SILO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,258
  • Shares Outstanding, K 4,484
  • Annual Sales, $ 70 K
  • Annual Income, $ -3,700 K
  • EBIT $ -4 M
  • EBITDA $ -4 M
  • 60-Month Beta -0.35
  • Price/Sales 58.55
  • Price/Cash Flow N/A
  • Price/Book 0.60
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.81
  • Most Recent Earnings $-0.22 on 11/12/24
  • Next Earnings Date 11/11/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7700 +23.32%
on 11/25/24
1.3400 -29.13%
on 11/12/24
-0.3704 (-28.06%)
since 11/11/24
3-Month
0.7700 +23.32%
on 11/25/24
1.3500 -29.66%
on 11/11/24
-0.2204 (-18.84%)
since 09/11/24
52-Week
0.7700 +23.32%
on 11/25/24
4.5000 -78.90%
on 07/18/24
-0.4904 (-34.06%)
since 12/11/23

Most Recent Stories

More News
Silo Pharma Collaborates with Kymanox for Development of Subcutaneous Insertion Device for SP-26 Ketamine Implant

Silo Pharma collaborates with Kymanox to develop a subcutaneous device for its ketamine implant targeting chronic pain.Quiver AI SummarySilo Pharma, Inc. has announced a collaboration with Kymanox to develop...

SILO : 0.9496 (+1.02%)
Silo Pharma, Inc. Announces Promising Preclinical Results for Dual-action Treatment SPC-15 Targeting PTSD and Severe Stress-related Conditions

Silo Pharma's SPC-15 shows promising dual-target efficacy in preclinical studies for treating severe stress-related psychiatric conditions.Quiver AI SummarySilo Pharma, Inc. announced promising results...

SILO : 0.9496 (+1.02%)
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons,...

IMC.AX : 0.084 (+2.44%)
SILO : 0.9496 (+1.02%)
LLY : 796.03 (-0.44%)
ACOR : 0.6610 (-24.86%)
TRVN : 1.5900 (-1.70%)
IMRN : 2.24 (+11.24%)
Global Alzheimer's Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

/PRNewswire/ -- Alzheimer's disease (AD) is a progressive and neurodegenerative disorder that attacks the brain's nerve cells or neurons, which results in loss...

SILO : 0.9496 (+1.02%)
LLY : 796.03 (-0.44%)
ACOR : 0.6610 (-24.86%)
TRVN : 1.5900 (-1.70%)
IMRN : 2.24 (+11.24%)
Silo Pharma’s SPC-15 Awarded U.S. Patent to Protect Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease

ENGLEWOOD CLIFFS, NJ – May 9,  2023 – Silo Pharma, Inc.  (NASDAQ: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...

SILO : 0.9496 (+1.02%)
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders

ENGLEWOOD CLIFFS, NJ – April 19, 2023 – Silo Pharma, Inc.  (NASDAQ:SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...

SILO : 0.9496 (+1.02%)
Silo Pharma (NASDAQ: SILO) Provides Update on Study of Ketamine Formulations for Fibromyalgia

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently announced that it had achieved a positive...

SILO : 0.9496 (+1.02%)
Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Fibromyalgia

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has filed a provisional patent...

SILO : 0.9496 (+1.02%)
Silo Pharma (NASDAQ: SILO) to Benefit as Study Supports Psychedelics in Treating Depression

In a study carried out between 2013 to 2016, researchers found that 8.1% of American adults aged 20 and over suffered from depression during any given 2-week period, with women nearly twice as likely than...

SILO : 0.9496 (+1.02%)
Silo Pharma (NASDAQ: SILO) Expands IP, Tech Rights for Treating Rare Stress-Related Conditions

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, was recently issued U.S. Patent 11,491,120 for SPC-15...

SILO : 0.9496 (+1.02%)

Business Summary

Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer's, and other rare neurological disorders. Silo Pharma. Inc. is based in ENGLEWOOD CLIFFS, NJ.

See More

Key Turning Points

3rd Resistance Point 1.0383
2nd Resistance Point 1.0091
1st Resistance Point 0.9794
Last Price 0.9496
1st Support Level 0.9205
2nd Support Level 0.8913
3rd Support Level 0.8616

See More

52-Week High 4.5000
Fibonacci 61.8% 3.0751
Fibonacci 50% 2.6350
Fibonacci 38.2% 2.1949
Last Price 0.9496
52-Week Low 0.7700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar